Latest News & Features
Refine Search
Big Pharma
With Brexit negotiations well under way, Nicola Dagg, global head of IP at Allen & Overy, says ensuring that all of the regulatory and compliance requirements are in place immediately after Britain leaves the EU is the most important aspect of negotiations for the life sciences. 25 August 2017
Americas
Brazil’s Ministry of Health has published the entire list of the 2017 proposals to be considered for the Partnership for Product Development. 25 August 2017
Americas
Law firm Cantor Colburn has achieved the highest rate of successful allowances for patent applications following section 101 rejections citing the Mayo and Myriad precedents, according to data compiled by research firm Juristat. 25 August 2017
Big Pharma
Pharmaceutical company AbbVie’s attempt to obtain an extension on its Humira patents has been rejected by an Australian court. 24 August 2017
Asia
The Indian Patent Office has approved pharmaceutical company Pfizer’s application to patent its Prevenar 13 (pneumococcal 7-valent conjugate) drug, despite claims by Médecins Sans Frontières that it is too obvious. 24 August 2017
Americas
The biggest challenges in the life sciences concern second medical use patents and incentives for innovation, according to Lydia McNally, vice president, head of patents, oncology at Novartis. 23 August 2017
Americas
German therapeutics developer Ethris has agreed a €25 million ($29 million) research deal with AstraZeneca focused on developing therapies for respiratory diseases. 23 August 2017
Americas
Gene-editing company CRISPR Therapeutics has partnered with the cancer centre at Massachusetts General Hospital to develop T cell therapies for treating the disease. 23 August 2017
Americas
Abbott Laboratories has fended off patent infringement claims filed by Enzo Biochem after convincing a US court that the patents did not describe the invention in a sufficient way. 22 August 2017
Asia-Pacific
Samsung’s biopharmaceutical arm Samsung Bioepis has agreed a deal with Takeda to tackle “unmet disease areas”, marking the South Korean company’s move into the novel drugs market. 22 August 2017